Humanoid Inc (HERB) Stock Analysis
Verdict: AVOID
Optical value trap: Extremly low multiples are invalidated by non-existent liquidity, declining growth, and opaque OTC reporting risks.
Investment score: 18/100
Analysis as of
Is Humanoid Inc stock worth reviewing? The TradeMates thesis
HERB presents as a classic 'Chinese OTC Value Trap' where on-paper assets do not translate to shareholder value.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Humanoid Inc opportunities and risks
What speaks for HERB
- Extreme Asset Discount
What speaks against HERB
- Total Liquidity Failure
Peers and competitors
- LMNR
- GGROU
- LOCL
- MAKE
- SDOT
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HERB | 0.6x | 0.2x | n/a | 33.5% | 33.4% | 58.1% |
| LMNR | n/a | 1.6x | n/a | -3.9% | -15.6% | -7.3% |
| GGROU | 12.7x | 1.3x | n/a | -0.0% | 10.1% | 1.9% |
| LOCL | n/a | 0.7x | n/a | 11.8% | -138.6% | -100.5% |
| SDOT | n/a | 0.1x | n/a | -1.3% | -86.4% | -31.5% |
| Peer median | n/a | 1.0x | n/a | -0.6% | -51.0% | -19.4% |
Frequently asked questions about Humanoid Inc (HERB)
Is HERB stock a good investment?
The TradeMates model rates Humanoid Inc as AVOID with an investment score of 18/100. HERB presents as a classic 'Chinese OTC Value Trap' where on-paper assets do not translate to shareholder value. This is algorithmic model output, not personal investment advice.
Is HERB stock a buy?
The TradeMates model verdict for HERB is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.